Global Briefs: Adare Pharma Solutions, Asahi Kasei & More
A roundup of news from Adare Pharma Solutions, dsm-firmenich, Asahi Kasei and Novavax. Highlights below.
M&A News
* Adare Pharma Solutions Completes Sale of Adare Biome Business Unit to DSM-Firmenich
General
* Asahi Kasei Moving Global HQ for Healthcare Business to US
COVID News
* Canada To Pay Novavax $350 M for Canceled COVID-19 Vaccine Order
M&A News
Adare Pharma Solutions Completes Sale of Adare Biome Business Unit to DSM-Firmenich
Dsm-firmenich has completed its EUR-275 million ($303 million) acquisition of Adare Biome, a developer and manufacturer of postbiotics and part of Adare Pharma Solutions, a CDMO of drug products and drug-delivery services. The acquisition was announced in April 2023.
Adare Biome’s key product is Lactéol, a branded supplement for relieving gut upsets. dsm-firmenich intends to extend the availability of Lactéol through its business-to-consumer unit, i-Health. Further development of postbiotic business-to-business ingredients will include opportunities in dietary supplements, early-life nutrition, medical nutrition, and nutritional improvement for the under-nourished.
Earlier this year (April 2023), DSM, a provider of ingredients for the life sciences and nutritional fields, merged with the flavors and fragrance company, Firmenich, to form dsm-firmenich. The newly combined company began trading as dsm-firmenich in early May (May 2023).
Source: dsm-firmenich and Adare Pharma Solutions
General
Asahi Kasei Moving Global HQ for Healthcare Business to US
Asahi Kasei has announced that it is moving the global headquarters of its Healthcare Business to the US, specifically to Chelmsford, Massachusetts, a suburb of Boston. The Primary Executive Officer for the Healthcare business and staff will be located to the existing Asahi Kasei offices in Chelmsford.
Source: Asahi Kasei
COVID News
Canada To Pay Novavax $350 M for Canceled COVID-19 Vaccine Order
Novavax, a Gaithersburg, Maryland-based vaccines company, has signed an amendment to its advanced purchase agreement with Canada under which Canada will pay Novavax $350 million for canceled COVID-19 vaccine orders.
Source: Novavax
